Recruiting soon

TRP-TriptansTryptophan Levels and Triptan Effectiveness in Migraine Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected at a single point in time - Cross-sectional
No DNA Sample
Who is being recruted

Brain Diseases+3

+ Central Nervous System Diseases

+ Migraine Disorders

From 18 to 50 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Control

Comparing exposures between individuals with and without disease in order to identify potential risk factors.
Observational
Study Start: November 2025
See protocol details

Summary

Principal SponsorUniversity Hospital, Clermont-Ferrand
Study ContactLise Laclautre
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2025

Actual date on which the first participant was enrolled.

Migraine is a significant health issue affecting people worldwide, leading to significant disability. Triptans are commonly used medications that help alleviate the pain and symptoms of migraines by affecting blood vessels and reducing inflammation. Despite their effectiveness, not all patients experience relief from triptans. This study focuses on understanding why some people do not respond well to these medications. It investigates the role of tryptophan, an essential amino acid, in influencing the effectiveness of triptans. Since tryptophan contributes to the production of important chemicals like serotonin, which are involved in managing migraines, understanding its role could help improve treatment for those who currently find triptans ineffective. The study observes patients with migraines to compare tryptophan levels in those who respond well to triptans and those who do not. Participants' blood samples are analyzed to measure tryptophan and its by-products. For those undergoing a lumbar puncture as part of their regular care, cerebrospinal fluid is also examined. Additionally, the study explores the potential link between tryptophan metabolism and conditions like inflammatory bowel disease, which could affect how the body absorbs and processes tryptophan. By identifying these connections, the study aims to enhance understanding and treatment options for migraine sufferers.

Official TitleTryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
NCT07177885
Principal SponsorUniversity Hospital, Clermont-Ferrand
Study ContactLise Laclautre
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

144 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-Control

These studies compare people who have a disease (cases) with those who don't (controls). The goal is to look back at previous exposures or risk factors to identify what might have contributed to the disease.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Brain DiseasesCentral Nervous System DiseasesMigraine DisordersNervous System DiseasesHeadache DisordersHeadache Disorders, Primary

Criteria

7 inclusion criteria required to participate
Cisgender women, premenopausal, aged 18 to 50 years.

Cisgender men, aged 18 to 50 years.

Diagnosed with migraine (according to ICHD-3 criteria).

Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022).

Show More Criteria

2 exclusion criteria prevent from participating
Patients under guardianship, curatorship, deprivation of liberty, or legal protection

Pregnant and breastfeeding women

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

CHU de Clermont-Ferrand

Clermont-Ferrand, FranceOpen CHU de Clermont-Ferrand in Google Maps
Recruiting soonOne Study Center
TRP-Triptans | Tryptophan Levels and Triptan Effectiveness in Migraine Patients | PatLynk